Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II clinical trial of TZ 101-fucosylated regulatory T cells for prevention of graft versus host disease in patients eligible for haematologic stem cell transplant.

Next Previous
X
Search
Trial Profile

Phase I/II clinical trial of TZ 101-fucosylated regulatory T cells for prevention of graft versus host disease in patients eligible for haematologic stem cell transplant.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TZ 101 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Targazyme

    • Most Recent Events

    • 20 Jul 2016 According to Targazyme media release, company has enrolled the first patient in this study.
    • 20 Jul 2016 Status changed from not yet recruiting to recruiting, as reported by Targazyme media release.
    • 27 Jul 2015 According to Targazyme media release, company received National Cancer Institute SBIR award as fund for conducting this study at The University of Texas MD Anderson Cancer Center and at the University of Minnesota.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top